<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug</h1>
  <ul>
<li>Analysts predict a revenue growth rate of 4.2% per annum over the next few years.</li>
<li>Given the current share price of US$84.71, the analyst consensus price target sits at US$101.75, representing a 20.8% potential upside.</li>
<li>The immediate impact has been a share price boost of 4.98% last month.</li>
<li>Over a five-year period, Merck’s total shareholder return, including share price and dividends, increased by 22.43%.</li>
<li>However, in the last year, the company underperformed compared to the US Pharmaceuticals industry, which returned 11.5%.</li>
<li>Merck recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company's 4.98% share price i</li>
<li>We've identified 1 weakness for Merck that you should be aware of.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/merck-mrk-gains-breakthrough-therapy-172809106.html">Source</a> · 2025-09-08T17:28:09+00:00</p>
</body>
</html>